Go Deep
SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,746 | -9.5 | 3.44 | 0.01 | 2,277.99 |
| Oct 2026 | 18,798 | -9.4 | 3.41 | 0.01 | 2,249.31 |
| Oct 2026 | 18,565 | -10.0 | 3.56 | 0.01 | 2,347.44 |
| Oct 2026 | 18,728 | -9.6 | 3.46 | 0.01 | 2,273.16 |
| Oct 2026 | 18,592 | -9.8 | 3.54 | 0.01 | 2,332.48 |
| Oct 2026 | 18,239 | -10.4 | 3.77 | 0.01 | 2,480.40 |
| Oct 2026 | 17,888 | -11.0 | 3.99 | 0.01 | 2,620.87 |
| Oct 2026 | 17,772 | -11.2 | 4.06 | 0.01 | 2,663.71 |
| Oct 2026 | 17,713 | -11.3 | 4.10 | 0.01 | 2,699.40 |
SpyGlass Pharma, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -19,864,000.0 | -13,818,000.0 | -12,555,228.0 | -9,815,772.0 |
| EPS | -0.6 | -0.7 | — | — |
SpyGlass Pharma, Inc. Revenue & Profit: Last 3 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 |
| Net Profit | -39,869,000.0 | -29,164,000.0 | -13,318,990.0 |
| EPS | -1.2 | -1.6 | -1.2 |
SpyGlass Pharma, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Total Assets | 115,866,000.0 | 23,318,000.0 | 41,149,466.0 |
| Total Liabilities | 214,703,000.0 | 83,792,000.0 | 74,134,984.0 |
| Total Equity | -98,837,000.0 | -60,474,000.0 | -32,985,518.0 |
Owes vs Owns
SpyGlass Pharma, Inc. owed $0.05 for every $1 it owned in Jun 2026, down from $1.80 in Dec 2023.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.05× | 1.85× | 3.59× | 1.80× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
SpyGlass Pharma, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 92.7%Fixed assets (tangible) 3.4%Other assets 3.5%
How it's funded — Dec 2025
Long-term debt 0.7%Payables 1.3%Other liabilities 98.0%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Assets | |||
| Cash & short-term investments | 107.4 | 16.3 | 40.3 |
| Receivables | 0.4 | 0.4 | 0.1 |
| Inventory | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 3.9 | 5.5 | 0.4 |
| Intangible assets | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 |
| Other assets | 4.1 | 1.2 | 0.3 |
| Liabilities & equity | |||
| Short-term debt | 0.0 | 0.4 | 0.0 |
| Long-term debt | 1.6 | 3.5 | 0.0 |
| Payables | 2.7 | 2.0 | 0.6 |
| Other liabilities | 210.4 | 77.9 | 73.5 |
| Shareholders' equity | -98.8 | -60.5 | -33.0 |
| Net tangible assets | -98.8 | -60.5 | -33.0 |
SpyGlass Pharma, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Operating Activities | -32,701,000.0 | -22,027,000.0 | -12,277,733.0 |
| Investing Activities | -11,794,000.0 | 22,261,000.0 | -20,486,228.0 |
| Financing Activities | 124,585,000.0 | 185,000.0 | 39,769,970.0 |